Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer

被引：41

作者：

Kelloff, GJ

Coffey, DS

Chabner, BA

Dicker, AP

Guyton, KZ

Nisen, PD

Soule, HR

D'Amico, AV

机构：

[1] NCI, Div Canc Treatment & Diag, Canc Imaging Program, Bethesda, MD 20892 USA

[2] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA

[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[4] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA

[5] CCS Associates, Mountain View, CA USA

[6] Abbott Labs, Global Oncol Dev, Abbott Pk, IL 60064 USA

[7] CaP CURE, Santa Monica, CA USA

[8] Brigham & Womens Hosp, Boston, MA 02115 USA

来源：

CLINICAL CANCER RESEARCH | 2004年 / 10卷 / 11期

关键词：

D O I：

10.1158/1078-0432.CCR-03-0788

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：3927 / 3933

页数：7

共 45 条

[1] Biology of prostate-specific antigen [J].

Balk, SP ;

Ko, YJ ;

Bubley, GJ .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :383-391

[2] Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen [J].

Bander, NH ;

Nanus, DM ;

Milowsky, MI ;

Kostakoglu, L ;

Vallabahajosula, S ;

Goldsmith, SJ .

SEMINARS IN ONCOLOGY, 2003, 30 (05) :667-677

[3] Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].

Baselga, J ;

Tripathy, D ;

Mendelsohn, J ;

Baughman, S ;

Benz, CC ;

Dantis, L ;

Sklarin, NT ;

Seidman, AD ;

Hudis, CA ;

Moore, J ;

Rosen, PP ;

Twaddell, T ;

Henderson, IC ;

Norton, L .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744

[4] Nadir prostate-specific antigen as a predictor of progression to an drogen-independent prostate cancer [J].

Benaim, EA ;

Pace, CM ;

Lam, PM ;

Roehrborn, CG .

UROLOGY, 2002, 59 (01) :73-78

[5] Prostate-specific antigen velocity and repeated measures of prostate-specific antigen [J].

Carter, HB ;

Pearson, JD .

UROLOGIC CLINICS OF NORTH AMERICA, 1997, 24 (02) :333-&

[6] LONGITUDINAL EVALUATION OF PROSTATE-SPECIFIC ANTIGEN LEVELS IN MEN WITH AND WITHOUT PROSTATE DISEASE [J].

CARTER, HB ;

PEARSON, JD ;

METTER, J ;

BRANT, LJ ;

CHAN, DW ;

ANDRES, R ;

FOZARD, JL ;

WALSH, PC .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (16) :2215-2220

[7] DETECTION OF ORGAN-CONFINED PROSTATE-CANCER IS INCREASED THROUGH PROSTATE-SPECIFIC ANTIGEN-BASED SCREENING [J].

CATALONA, WJ ;

SMITH, DS ;

RATLIFF, TL ;

BASLER, JW .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (08) :948-954

[8] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].

Cobleigh, MA ;

Vogel, CL ;

Tripathy, D ;

Robert, NJ ;

Scholl, S ;

Fehrenbacher, L ;

Wolter, JM ;

Paton, V ;

Shak, S ;

Lieberman, G ;

Slamon, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648

[9] Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer [J].

D'Amico, AV ;

Cote, K ;

Loffredo, M ;

Renshaw, AA ;

Schultz, D .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (23) :4567-4573

[10] Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer [J].

D'Amico, AV ;

Whittington, R ;

Malkowicz, SB ;

Schultz, D ;

Blank, K ;

Broderick, GA ;

Tomaszewski, JE ;

Renshaw, AA ;

Kaplan, I ;

Beard, CJ ;

Wein, A .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :969-974

← 1 2 3 4 5 →